Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01559272 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 328
- Enrollment target
- 20
- Study locations
NCT01559272: Completed Phase 1 study of Schizophrenia, sponsored by Janssen Research & Development.
NCT01559272 is a Phase 1 study of Schizophrenia that has completed, run by Janssen Research & Development. The registered enrollment target is 328 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01559272, a Phase 1 study of Schizophrenia, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 328 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability of a paliperidone palmitate 3-month formulation in patients with schizophrenia.
Conditions Studied
Interventions
- DRUG Paliperidone IR (Period 1)
- DRUG Paliperidone palmitate F015 (Panel A: treatment group 1)
- DRUG Paliperidone palmitate F015 (Panel A: treatment group 2)
- DRUG Paliperidone palmitate F015 (Panel B: treatment group 1)
- DRUG Paliperidone palmitate F015 (Panel B: treatment group 2)
Study Locations (20)
Other
- - Aalst
- - Diest
- - Burgas
- - Zagreb
- - Beer Yaakov
- - Hod HaSharon
- - Ramat Gan
- - Johor Bahru
- - Kuala Lumpur
- - Perak
California
- - Cerritos
- - Garden Grove
- - Glendale
- - National City
- - Paramount
Texas
- - Austin
- - DeSoto
Arkansas
- - Little Rock
Georgia
- - Atlanta
Pennsylvania
- - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2008-02-21 |
| Est. Completion | 2014-05-24 |
| Phase | Phase 1 |
What the finished NCT01559272 record still lists
NCT01559272 is an interventional study that assigns participants to a tested intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 5 interventions - of which Paliperidone IR (Period 1) is the first listed.
NCT01559272 names 20 study sites across 6 states, led by Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT01559272 about?
NCT01559272 is a clinical study titled "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia". The purpose of this study is to assess the pharmacokinetics, safety, and tolerability of a paliperidone palmitate 3-month formulation in patients with schizophrenia.
What is the current status of trial NCT01559272?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 328 participants. The study started on 2008-02-21. Estimated completion is 2014-05-24.
What conditions does trial NCT01559272 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT01559272?
The interventions under investigation include: Paliperidone IR (Period 1) (DRUG), Paliperidone palmitate F015 (Panel A: treatment group 1) (DRUG), Paliperidone palmitate F015 (Panel A: treatment group 2) (DRUG), Paliperidone palmitate F015 (Panel B: treatment group 1) (DRUG), Paliperidone palmitate F015 (Panel B: treatment group 2) (DRUG).
Who is sponsoring clinical trial NCT01559272?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01559272 being conducted?
This trial has 20 study locations across Arkansas, California, Georgia, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01559272's enrollment target sits among peer trials
328 51st of 315 higher than 265 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
- NCT05548413 · 328 participants · NA
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
- NCT06393725 · 328 participants · NA
Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI